The Germany Continuous Glucose Monitoring (CGM) market is forecast to grow at a CAGR of 28.8%, reaching USD 877.8 million in 2031 from USD 247.7 million in 2026.
Continuous sugar monitoring (CGM), sometimes referred to as sugar continuous glucose monitoring, automatically monitors blood glucose throughout the day. Making more educated choices about maintaining daily medication use, a healthy diet, and physical activity can be aided with real-time glucose monitoring. A small sensor used in CGM is implanted beneath the skin, often on the arm or abdomen. The sensor picks up interstitial glucose, which is present in the intercellular fluid. The sensor examines the glucose level every few minutes, and wireless data transmission sends the results to a monitor.
Moreover, the closed-loop bionic/artificial pancreas has been given a blueprint because of CGMS-based technologies. Thus, businesses that manufacture glucose monitoring devices concentrate largely on creating novel and cutting-edge CGMS. It has several applications for healthcare settings (hospital ICUs, diagnostic centers, and clinics), for all age groups, and geographical locations. A growing awareness of diabetes preventative care, new product debuts, government efforts, and the CGM device market are the major market drivers for CGM Market.
Germany adopts technologies like continuous glucose monitoring more quickly than other emerging nations. Unprecedented interest in remote care from patients and providers as well as the removal of many long-standing legislative restrictions have been brought about through crisis management by the government. Many conveniences in managing blood glucose levels are made possible by technological developments and advancements. The flexibility of blood glucose monitoring equipment is improving as a result of people's increasing understanding of cutting-edge diabetic technologies. To increase their market share significantly, top manufacturers are concentrating on technical advancements and creating cutting-edge goods.
Increasing prevalence of diabetes to surge the market for CGM in Germany.
The German Diabetes Center estimates that at least 7.2% of the population in Germany presently has diabetes, and that number will rise dramatically over the next 20 years. Obesity, a poor diet, and lack of exercise are the primary causes of the rise in newly diagnosed Type 1 and Type 2 diabetes cases. Healthcare spending and the fastening incidence and prevalence of diabetes individuals are signs of market expansion of continuous glucose monitoring in Germany.
Government initiatives to surge growth in Germany.
A cap on out-of-pocket medical expenses and coverage of all medically required treatments, including insulin medications, are mandated by German law for public insurance plans. T1 International, an organization that advocates for individuals with diabetes, claims that out-of-pocket expenses for German diabetes patients are among the lowest in the whole globe. In Germany, strict government rules and supportive WHO regulations are incentivizing businesses to create novel goods. These products' market penetration in Germany helps regional clinical research organizations (CROs) with their clinical research trials and assures managerial simplicity, which speeds up the discovery process for diabetic patients.
Market Key Developments
In October 2022, by making the G7 continuous glucose monitoring system accessible in the United Kingdom, Ireland, Germany, Austria, and Hong Kong, Dexcom started the worldwide deployment of the product.
In April 2022, to lessen the burden on persons with diabetes, CamDiab, Abbott, and Ypsomed collaborated to create and sell an integrated automated insulin delivery (AID) system in Germany.
| Report Metric | Details |
|---|---|
| Study Period | 2021 to 2031 |
| Historical Data | 2021 to 2024 |
| Base Year | 2025 |
| Forecast Period | 2026 – 2031 |
| Companies |
|
Report Metric | Details |
Market Size Value in 2021 | US$208.886 million |
Market Size Value in 2028 | US$730.683 million |
Growth Rate | CAGR of 19.59% from 2021 to 2028 |
Base Year | 2021 |
Forecast Period | 2023 – 2028 |
Forecast Unit (Value) | USD Million |
Segments Covered | Application and End-User Industry |
Companies Covered | Dexcom, Inc., Abbott Laboratories, Medtronic plc, Roche Diabetes Care, Inc., Senseonics Holdings, Inc., Ascensia Diabetes Care, Insulet Corporation[1], Tandem Diabetes Care, Inc., Ypsomed AG, Diabetizer GmbH & Co. KG |
Customization Scope | Free report customization with purchase |
Segmentation:
By Application
Diabetes Patients
Critical Patients
By End-User Industry
Hospitals
Diagnostic Centers & Clinics
Home Care